Business · 1 sources covering this

Eli Lilly Gets US FDA Nod For Once-Weekly Onswik Insulin For Type 2 Diabetes

Lilly’s FDA approval is based on the QWINT Phase 3 programme, which evaluated Onswik in more than 3,400 adults with type 2 diabetes across four clinical trials.

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

NDTVCenter·1h ago
Eli Lilly Gets US FDA Nod For Once-Weekly Onswik Insulin For Type 2 Diabetes
Lilly’s FDA approval is based on the QWINT Phase 3 programme, which evaluated Onswik in more than 3,400 adults with type 2 diabetes across four clinical trials.
Read at NDTV →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/237a903caf29640f704fc3f82fea9cdc06c3b61f"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Eli Lilly Gets US FDA Nod For Once-Weekly Onswik Insulin For Type 2 Diabetes"></iframe>

Eli Lilly Gets US FDA Nod For Once-Weekly Onswik Insulin For Type 2 Diabetes

How 1 sources are covering this

Eli Lilly Gets US FDA Nod For Once-Weekly Onswik Insulin For Type 2 Diabetes

More from Business

Trump Says US, China Want To Leave AI Exactly Where It Is' Amid Global Safety Debate

NSE debuts at ₹1,800; MD & CEO says India's growth will drive exchange

'Biggest Risk Is Regulatory Risk': Nithin Kamath Weighs In As IRDAI Proposal Sparks 34% PB Fintech Rout

The overlooked part of estate planning: Choosing your spouse's adviser

Reader

Trust & legal

Across the network